{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:56:53Z","timestamp":1781614613416,"version":"3.54.5"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>T-prolymphocytic leukemia (T-PLL) is a rare mature T-cell neoplasm with poor prognosis that mainly affects elderly people. Alemtuzumab is widely considered as first-line therapy, but almost all patients relapse within one year, if not consolidated by an allogeneic stem cell transplantation. The improved understanding of T-PLL-specific molecular pathomechanisms gained over the last years suggested new potential therapeutic targets (epigenetic dysregulation, defective DNA damage response, aberrant cell cycle regulation, dysregulated prosurvival pathways), which were recently evaluated in a preclinical drug response study. In addition, existing genomewide T-PLL gene expression profiles enabled the identification of three robust T-PLL gene expression subgroups differing in cellular processes like immune response, cellular respiration, cell proliferation, apoptosis, or migration. So far, these T-PLL gene expression subgroups were not considered in preclinical drug response analyses, but recently published drug response screens and corresponding already publicly available gene expression profiles offer the great opportunity to integrate both data types. Therefore, we computationally analyzed samples from 34 T-PLL patients of two comparable cohorts for their response to in total 11 drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No T-PLL subgroup-specific differences or sex differences in response to the tested drugs were found. With respect to the underlying drug dosage schemes, venetoclax and cladribine were most effective in erasing T-PLL cancer cells among both cohorts. Also dinaciclib, idasanutlin, romidepsin, and KRT-232, which were only tested in one of both cohorts, were very effective for all or most of the T-PLL patient samples. For the three drugs bendamustine, cladribine, and fludarabine, which were only effective in a subset of the T-PLL samples, an exploratory differential gene expression analysis predicted drug-specific genes that distinguished between strongly and not strongly responding samples. In-depth annotation and literature analyses showed that many of these genes are known to play a role in leukemias or other types of cancer. Many of these genes were also confirmed by a direct correlation analysis between gene expression levels and drug responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The absence of T-PLL gene expression subgroup-specific drug responses across the tested drugs can be important for the design of future drug screens and may ease potential clinical trials. Genes associated with drug-specific responses could be useful for improved patient stratification and may help to characterize molecular settings associated with effective responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13062-025-00701-3","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:06:30Z","timestamp":1761552390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups"],"prefix":"10.1186","volume":"20","author":[{"given":"Nathan","family":"Mikhaylenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Timonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"1","key":"701_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1385\/MO:23:1:17","volume":"23","author":"CE Dearden","year":"2006","unstructured":"Dearden CE. T-cell prolymphocytic leukemia. Med Oncol. 2006;23(1):17\u201322. https:\/\/doi.org\/10.1385\/MO:23:1:17.","journal-title":"Med Oncol"},{"issue":"1","key":"701_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/08998280.2013.11928902","volume":"26","author":"RL Graham","year":"2013","unstructured":"Graham RL, Cooper B, Krause JR. T-cell prolymphocytic leukemia. Proc (Bayl Univ Med Cent). 2013;26(1):19\u201321. https:\/\/doi.org\/10.1080\/08998280.2013.11928902.","journal-title":"Proc (bayl Univ Med Cent)"},{"issue":"2","key":"701_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11899-020-00566-5","volume":"15","author":"T Braun","year":"2020","unstructured":"Braun T, Jan J, Wahnschaffe L, Herling M. Advances and perspectives in the treatment of T-PLL. Curr Hematol Malig Rep. 2020;15(2):113\u201324. https:\/\/doi.org\/10.1007\/s11899-020-00566-5.","journal-title":"Curr Hematol Malig Rep"},{"key":"701_CR4","doi-asserted-by":"publisher","first-page":"110107","DOI":"10.1016\/j.biopha.2020.110107","volume":"126","author":"S Sun","year":"2020","unstructured":"Sun S, Fang W. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene. Biomed Pharmacother. 2020;126:110107. https:\/\/doi.org\/10.1016\/j.biopha.2020.110107.","journal-title":"Biomed Pharmacother"},{"key":"701_CR5","doi-asserted-by":"publisher","unstructured":"Braun T, Dechow A, Friedrich G, Seifert M, Stachelscheid J, Herling M. Advanced pathogenetic concepts in T-cell prolymphocytic leukemia and their translational impact. Front Oncol. 2021;11(775363). https:\/\/doi.org\/10.3389\/fonc.2021.775363.","DOI":"10.3389\/fonc.2021.775363"},{"issue":"2","key":"701_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2004-01-0002","volume":"104","author":"M Herling","year":"2004","unstructured":"Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004;104(2):328\u201335. https:\/\/doi.org\/10.1182\/blood-2004-01-0002.","journal-title":"Blood"},{"issue":"14","key":"701_CR7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood.2019000402","volume":"134","author":"PB Staber","year":"2019","unstructured":"Staber PB, Herling M, Bellido, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019;134(14):1132\u201343. https:\/\/doi.org\/10.1182\/blood.2019000402.","journal-title":"Blood"},{"issue":"12","key":"701_CR8","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","volume":"78","author":"E Matutes","year":"1991","unstructured":"Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, Sempere A, Catovsky D. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78(12):3269\u201374.","journal-title":"Blood"},{"issue":"3","key":"701_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3816\/CLM.2005.n.051","volume":"6","author":"F Ravandi","year":"2005","unstructured":"Ravandi F, O\u2019Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, et al. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2005;6(3):234\u201339. https:\/\/doi.org\/10.3816\/CLM.2005.n.051.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"6","key":"701_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.18632\/oncotarget.26595","volume":"10","author":"A Schrader","year":"2019","unstructured":"Schrader A, Braun T, Herling M. The dawn of a new era in treating T-PLL. Oncotarget. 2019;10(6):626\u201328. https:\/\/doi.org\/10.18632\/oncotarget.26595.","journal-title":"Oncotarget"},{"issue":"7823","key":"701_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0140-6736(73)93135-8","volume":"2","author":"D Catovsky","year":"1973","unstructured":"Catovsky D, Galetto J, Okos A, Galton DA, Wiltshaw E, Stathopoulos G. Prolymphocytic leukaemia of B and T cell type. Lancet. 1973;2(7823):232\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(73)93135-8.","journal-title":"Lancet"},{"key":"701_CR12","doi-asserted-by":"publisher","unstructured":"Dearden CE. Management of prolymphocytic leukemia. Hematology Am Soc Hematol educ program. 2015;2015:361\u201367. https:\/\/doi.org\/10.1182\/asheducation-2015.1.361.","DOI":"10.1182\/asheducation-2015.1.361"},{"issue":"14","key":"701_CR13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.2019002303","volume":"134","author":"AM Risitano","year":"2019","unstructured":"Risitano AM. T-PLL: harmonizing criteria for research. Blood. 2019;134(14):1113\u201314. https:\/\/doi.org\/10.1182\/blood.2019002303.","journal-title":"Blood"},{"issue":"15","key":"701_CR14","doi-asserted-by":"publisher","first-page":"12106","DOI":"10.3390\/ijms241512106","volume":"24","author":"M Gutierrez","year":"2023","unstructured":"Gutierrez M, Bladek P, Goksu B, Murga-Zamalloa C, Bixby D, Wilcox R. T-Cell prolymphocytic leukemia: diagnosis, pathogenesis, and treatment. Int J Mol Sci. 2023;24(15):12106. https:\/\/doi.org\/10.3390\/ijms241512106.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"701_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/gcc.1141","volume":"31","author":"J Soulier","year":"2001","unstructured":"Soulier J, Pierron J, Vecchione D, Garand R, Brizard F, Sigaux F, Stern MH, Aurias A. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2001;31(3):248\u201354. https:\/\/doi.org\/10.1002\/gcc.1141.","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"701_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2007-07-101519","volume":"111","author":"M Herling","year":"2008","unstructured":"Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111(1):328\u201337. https:\/\/doi.org\/10.1182\/blood-2007-07-101519.","journal-title":"Blood"},{"issue":"1","key":"701_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41467-017-02688-6","volume":"9","author":"A Schrader","year":"2018","unstructured":"Schrader A, Crispatzu G, Oberbeck S, Mayer P, P\u00fctzer S, Jan J, et al. Actionable perturbations of damage responses by TCL1\/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018;9(1):697. https:\/\/doi.org\/10.1038\/s41467-017-02688-6.","journal-title":"Nat Commun"},{"issue":"9","key":"701_CR18","doi-asserted-by":"publisher","first-page":"0274463","DOI":"10.1371\/journal.pone.0274463","volume":"17","author":"N Mikhaylenko","year":"2022","unstructured":"Mikhaylenko N, Wahnschaffe MLH, Roeder I, Seifert M. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia. PLoS One. 2022;17(9):0274463. https:\/\/doi.org\/10.1371\/journal.pone.0274463.","journal-title":"PLoS One"},{"issue":"24","key":"701_CR19","first-page":"5452","volume":"57","author":"MG Narducci","year":"1997","unstructured":"Narducci MG, Stoppacciaro A, Imada K, Uchiyama T, Virgilio L, Lazzeri C, Croce CM, Russo G. TCL1 is overexpressed in patients affected by adult T-cell leukemias. Cancer Res. 1997;57(24):5452\u201356.","journal-title":"Cancer Res"},{"issue":"40","key":"701_CR20","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1038\/sj.onc.1204596","volume":"20","author":"Y Pekarsky","year":"2001","unstructured":"Pekarsky Y, Hallas C, Croce CM. The role of TCL1 in human T-cell leukemia. Oncogene. 2001;20(40):5638\u201343. https:\/\/doi.org\/10.1038\/sj.onc.1204596.","journal-title":"Oncogene"},{"issue":"9","key":"701_CR21","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","volume":"124","author":"MJ Kiel","year":"2014","unstructured":"Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, Schrader A, Li B, Li JZ, Ozel AB, Betz BL, Miranda RN, Medeiros LJ, Zhao L, Herling M, Lim MS, Elenitoba-Johnson KSJ. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014;124(9):1460\u201372. https:\/\/doi.org\/10.1182\/blood-2014-03-559542.","journal-title":"Blood"},{"issue":"2","key":"701_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/bjh.13952","volume":"173","author":"C L\u00f3pez","year":"2016","unstructured":"L\u00f3pez C, Bergmann AK, Paul U, Murga Penas EM, Nagel I, Betts MJ, et al. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol. 2016;173(2):265\u201373. https:\/\/doi.org\/10.1111\/bjh.13952.","journal-title":"Br J Haematol"},{"key":"701_CR23","doi-asserted-by":"publisher","unstructured":"Wahnschaffe L, Braun T, Timonen S, Giri AK, Schrader A, Wagle P, Almusa H, Johansson P, Bellanger D, L\u00f3pez C, Haferlach C, Stern M-H, D\u00fcrig J, Siebert R, Mustjoki S, Aittokallio T, Herling M. JAK\/STAT-Activating genomic alterations are a hallmark of T-PLL. Cancers. 2019;11(12). https:\/\/doi.org\/10.3390\/cancers11121833.","DOI":"10.3390\/cancers11121833"},{"issue":"1","key":"701_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3324\/haematol.2020.267500","volume":"187-200","author":"T Braun","year":"2022","unstructured":"Braun T, Glass M, Wahnschaffe L, Otte M, Mayer P, Franitza M, Altm\u00fcller J, Hallek M, H\u00fcttelmaier S, Schrader A, Herling M. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways. Hematologica. 2022;187-200(1):143\u201353. https:\/\/doi.org\/10.3324\/haematol.2020.267500.","journal-title":"Hematologica"},{"key":"701_CR25","doi-asserted-by":"publisher","unstructured":"Erkeland SJ, Stavast CJ, Schilperoord-Vermeulen J, Collo GD, Werken HJG, Leon LG, Van Hoven-Beijen A, Van Zuijen I, Mueller M, Bindels EM, De Ridder D, Kappers-Klunne MC, Van Lom K, Velden VHJ, Langerak AW. The miR-200c\/141-ZEB2-TGF\u03b2 axis is aberrant in human T-cell prolymphocytic leukemia. Hematologica. 2022;107(1):143\u201353. https:\/\/doi.org\/10.3324\/haematol.2020.263756.","DOI":"10.3324\/haematol.2020.263756"},{"issue":"22","key":"701_CR26","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1182\/blood-2012-01-380139","volume":"118","author":"CE Dearden","year":"2011","unstructured":"Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011;118(22):5799\u2013802. https:\/\/doi.org\/10.1182\/blood-2012-01-380139.","journal-title":"Blood"},{"issue":"3","key":"701_CR27","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","volume":"120","author":"C Dearden","year":"2012","unstructured":"Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120(3):538\u201351. https:\/\/doi.org\/10.1182\/blood-2012-01-380139.","journal-title":"Blood"},{"issue":"12","key":"701_CR28","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.27972","volume":"119","author":"G Hopfinger","year":"2013","unstructured":"Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink A-M, et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. 2013;119(12):2258\u201367. https:\/\/doi.org\/10.1002\/cncr.27972.","journal-title":"Cancer"},{"issue":"23","key":"701_CR29","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood-2017-05-785683","volume":"130","author":"B Boidol","year":"2017","unstructured":"Boidol B, Kornauth C, Kouwe E, Prutsch N, Kazianka L, G\u00fcltekin S, et al. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood. 2017;130(23):2499\u2013503. https:\/\/doi.org\/10.1182\/blood-2017-05-785683.","journal-title":"Blood"},{"issue":"3","key":"701_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/10428194.2018.1488253","volume":"60","author":"N Pflug","year":"2019","unstructured":"Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, et al. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk Lymphoma. 2019;60(3):649\u201357. https:\/\/doi.org\/10.1080\/10428194.2018.1488253.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"701_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/10428194.2019.1660967","volume":"21","author":"M Alfayez","year":"2020","unstructured":"Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, et al. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma. 2020;21(2):445\u201349. https:\/\/doi.org\/10.1080\/10428194.2019.1660967.","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"701_CR32","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood.2020007303","volume":"137","author":"C Herbaux","year":"2021","unstructured":"Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, et al. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021;137(25):3495\u2013506. https:\/\/doi.org\/10.1182\/blood.2020007303.","journal-title":"Blood"},{"issue":"1","key":"701_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000507415","volume":"144","author":"L Wahnschaffe","year":"2021","unstructured":"Wahnschaffe L, Herling M. What to look out for when transplanting T-Cell prolymphocytic leukemia. Acta Haematol. 2021;144(1):1\u20133. https:\/\/doi.org\/10.1159\/000507415.","journal-title":"Acta Haematol"},{"issue":"3","key":"701_CR34","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/leu.2017.252","volume":"32","author":"EI Andersson","year":"2018","unstructured":"Andersson EI, P\u00fctzer S, Yadav B, Dufva O, Khan S, He L, et al. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2018;32(3):774\u201378. https:\/\/doi.org\/10.1038\/leu.2017.252.","journal-title":"Leukemia"},{"key":"701_CR35","doi-asserted-by":"publisher","unstructured":"Pytlik R, Polgarova K, Karolova J, Klener P. Current immunotherapy approaches in non-hodgkin lymphomas. Nato Adv Sci Inst Se. 2020;8(4). https:\/\/doi.org\/10.3390\/vaccines8040708.","DOI":"10.3390\/vaccines8040708"},{"key":"701_CR36","doi-asserted-by":"publisher","first-page":"204062072093376","DOI":"10.1177\/2040620720933761","volume":"11","author":"P Johansson","year":"2020","unstructured":"Johansson P, Dierichs L, Klein-Hitpass L, Bergmann AK, M\u00f6llmann M, Menninger S, Habenberger P, Klebl B, Siveke JT, D\u00fchrsen U, Choidas A, D\u00fcrig J. Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia. Ther Adv Hematol. 2020;11, 2040620720933761 (https:\/\/doi.org\/10.1177\/2040620720933761.","journal-title":"Ther Adv Hematol"},{"key":"701_CR37","doi-asserted-by":"publisher","unstructured":"Cuesta-Mateos C, Fuentes P, Schrader A, Ju\u00e1rez-S\u00e1nchez R, Loscertales J, Mateu-Albero T, Vega-Piris L, Espartero-Santos M, Marcos-Jimenez A, S\u00e1nchez-L\u00f3pez BA, P\u00e9rez-Garc\u00eda Y, Jungherz D, Oberbeck S, Wahnschaffe L, Kreutzman A, Andersson EI, Mustjoki S, Faber E, Urzainqui A, Fresno M, Stamatakis K, Alfranca A, Terr\u00f3n F, Herling M, Toribio ML, Mu\u00f1oz-Calleja C. CCR7 as a novel therapeutic target in T-cell prolymphocytic leukemia. Biomark Res. 2020;8(54). https:\/\/doi.org\/10.1186\/s40364-020-00234-z.","DOI":"10.1186\/s40364-020-00234-z"},{"key":"701_CR38","doi-asserted-by":"publisher","unstructured":"Jan SJ, Timonen B, Jiang T, Ianevski Q, Peng A, Y, et al. Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated Apoptotic responses. Blood. 2024;144(15):1595\u2013610. https:\/\/doi.org\/10.1182\/blood.2023022884.","DOI":"10.1182\/blood.2023022884"},{"issue":"6","key":"701_CR39","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3390\/cancers12061696","volume":"12","author":"M Seifert","year":"2020","unstructured":"Seifert M, Schackert G, Temme A, Schr\u00f6ck E, Deutsch A, Klink B. Molecular characterization of astrocytoma progression towards secondary glioblastomas utilizing patient-matched tumor pairs. Cancers. 2020;12(6):1696. https:\/\/doi.org\/10.3390\/cancers12061696.","journal-title":"Cancers"},{"issue":"6","key":"701_CR40","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882\u201383. https:\/\/doi.org\/10.1093\/bioinformatics\/bts034.","journal-title":"Bioinformatics"},{"key":"701_CR41","doi-asserted-by":"publisher","unstructured":"Ritz C, Baty F, Streibig JC, Gerhard D. Dose-response analysis using R. PLoS One. 2015;10(12):0146021. https:\/\/doi.org\/10.1371\/journal.pone.0146021.","DOI":"10.1371\/journal.pone.0146021"},{"issue":"8","key":"701_CR42","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/bioinformatics\/btv723","volume":"32","author":"P Smirnov","year":"2016","unstructured":"Smirnov P, Safikhani Z, El-Hachem N, Wang D, She A, Olsen C, et al. PharmacoGx: an R package for analysis of large pharmacogenomic datasets. Bioinformatics. 2016;32(8):1244\u201346. https:\/\/doi.org\/10.1093\/bioinformatics\/btv723.","journal-title":"Bioinformatics"},{"issue":"11","key":"701_CR43","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","volume":"36","author":"S Potdar","year":"2020","unstructured":"Potdar S, Ianevski A, Mpindi J-P, Bychkov D, Fiere C, Ianevski P, et al. Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics. 2020;36(11):3602\u201304. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa138.","journal-title":"Bioinformatics"},{"key":"701_CR44","doi-asserted-by":"publisher","DOI":"10.32614\/CRAN.package.MESS","volume-title":"MESS: miscellaneous esoteric statistical scripts","author":"CT Ekstrom","year":"2023","unstructured":"Ekstrom CT. MESS: miscellaneous esoteric statistical scripts. 2023. https:\/\/doi.org\/10.32614\/CRAN.package.MESS. R package version 0.5.12."},{"key":"701_CR45","doi-asserted-by":"publisher","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","DOI":"10.1093\/nar\/gkv007"},{"issue":"3","key":"701_CR46","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00357-014-9161-z","volume":"31","author":"F Murtagh","year":"2014","unstructured":"Murtagh F, Legendre P. Ward\u2019s hierarchical agglomerative clustering method: Which algorithms implement ward\u2019s criterion? J Classif. 2014;31(3):274\u201395. https:\/\/doi.org\/10.1007\/s00357-014-9161-z.","journal-title":"J Classif"},{"issue":"1","key":"701_CR47","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B. 1995;57(1):289\u2013300.","journal-title":"J Roy Stat Soc Ser B"},{"key":"701_CR48","doi-asserted-by":"crossref","unstructured":"Safran M, Dalah I, Alexander J, Rosen N, Stein TI, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, et al. GeneCards version 3: the human gene integrator. Database. 2010 (2010;020.","DOI":"10.1093\/database\/baq020"},{"key":"701_CR49","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/nar\/gks1082","volume":"41","author":"J-L Huret","year":"2013","unstructured":"Huret J-L, Ahmad M, Arsaban M, Bernheim A, Cigna J, Desangles F, et al. Atlas of genetics and cytogenetics in oncology and haematology in 2013. Nucleic Acids Res. 2013;41((Database issue)), 920\u201324. https:\/\/doi.org\/10.1093\/nar\/gks1082.","journal-title":"Nucleic Acids Res"},{"key":"701_CR50","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/nar\/gkw1012","volume":"45","author":"N Rappaport","year":"2017","unstructured":"Rappaport N, Twik M, Plaschkes I, Nudel R, Stein TI, Levitt J, et al. MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. Nucleic Acids Res. 2017;45((D1)), 877\u201387. https:\/\/doi.org\/10.1093\/nar\/gkw1012.","journal-title":"Nucleic Acids Res"},{"key":"701_CR51","unstructured":"PubMed Central (PMC) [Internet] Bethesda (MD): 2000. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information."},{"issue":"4","key":"701_CR52","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/onc.2010.422","volume":"30","author":"S-H Goh","year":"2011","unstructured":"Goh S-H, Hong S-H, Hong S-H, Lee B-C, Ju M-H, Jeong J-S, et al. eIf3m expression influences the regulation of tumorigenesis-related genes in human colon cancer. Oncogene. 2011;30(4):398\u2013409. https:\/\/doi.org\/10.1038\/onc.2010.422.","journal-title":"Oncogene"},{"issue":"1\u20132","key":"701_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cytogfr.2005.09.008","volume":"17","author":"AB Roberts","year":"2006","unstructured":"Roberts AB, Tian F, Byfield S, Stuelten C, Ooshima A, Saika S, et al. Smad3 is key to tgf-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev. 2006;17(1\u20132):19\u201327. https:\/\/doi.org\/10.1016\/j.cytogfr.2005.09.008.","journal-title":"Cytokine Growth Factor Rev"},{"key":"701_CR54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.canlet.2016.12.011","volume":"388","author":"K Huang","year":"2017","unstructured":"Huang K, Yang C, Wang Q-X, Li Y-S, Fang C, Tan Y-L, et al. The CRISPR\/Cas9 system targeting EGFR exon 17 abrogates NF-\u03baB activation via epigenetic modulation of UBXN1 in EGFRwt\/vIII glioma cells. Cancer Lett. 2017;388:269\u201380. https:\/\/doi.org\/10.1016\/j.canlet.2016.12.011.","journal-title":"Cancer Lett"},{"issue":"1","key":"701_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12943-019-1046-7","volume":"18","author":"L Wang","year":"2019","unstructured":"Wang L, Long H, Zheng Q, Bo X, Xiao X, Li B. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer. 2019;18(1):119. https:\/\/doi.org\/10.1186\/s12943-019-1046-7.","journal-title":"Mol Cancer"},{"issue":"1","key":"701_CR56","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12885-017-3438-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Yin W, Shi C. E3 ubiquitin ligase, RNF139, inhibits the progression of tongue cancer. BMC Cancer. 2017;17(1):452. https:\/\/doi.org\/10.1186\/s12885-017-3438-7.","journal-title":"BMC Cancer"},{"issue":"3","key":"701_CR57","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/hep.28684","volume":"64","author":"C Ploeger","year":"2016","unstructured":"Ploeger C, Waldburger N, Fraas A, Goeppert B, Pusch S, Breuhahn K, et al. Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma. Hepatology. 2016;64(3):828\u201342. https:\/\/doi.org\/10.1002\/hep.28684.","journal-title":"Hepatology"},{"issue":"12","key":"701_CR58","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1111\/1759-7714.13976","volume":"12","author":"C Liu","year":"2021","unstructured":"Liu C, Tang J, Duan X, Du Y, Wang X, Cui Y. DDX10 promotes human lung carcinoma proliferation by U3 small nucleolar ribonucleoprotein IMP4. Thorac Cancer. 2021;12(12):1873\u201380. https:\/\/doi.org\/10.1111\/1759-7714.13976.","journal-title":"Thorac Cancer"},{"issue":"1","key":"701_CR59","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12885-018-4524-1","volume":"18","author":"X Wei","year":"2018","unstructured":"Wei X, Zhang K, Qin H, Zhu J, Qin Q, Yu Y, et al. GMDS knockdown impairs cell proliferation and survival in human lung adenocarcinoma. BMC Cancer. 2018;18(1):600. https:\/\/doi.org\/10.1186\/s12885-018-4524-1.","journal-title":"BMC Cancer"},{"issue":"7","key":"701_CR60","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3967\/bes2015.072","volume":"28","author":"Q Ma","year":"2015","unstructured":"Ma Q, Zhang Y, Meng R, Xie KM, Xiong Y, Lin S, et al. MAGI3 suppresses glioma cell proliferation via upregulation of PTEN expression. Biomed Environ Sci. 2015;28(7):502\u201309. https:\/\/doi.org\/10.3967\/bes2015.072.","journal-title":"Biomed Environ Sci"},{"issue":"7","key":"701_CR61","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1200\/JCO.2011.38.0345","volume":"30","author":"H Xu","year":"2012","unstructured":"Xu H, Cheng C, Devidas M, Pei D, Fan Y, Yang W, et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2012;30(7):751\u201357. https:\/\/doi.org\/10.1200\/JCO.2011.38.0345.","journal-title":"J Clin Oncol"},{"issue":"13","key":"701_CR62","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1182\/blood-2011-06-275610","volume":"118","author":"F Malavasi","year":"2011","unstructured":"Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011;118(13):3470\u201378. https:\/\/doi.org\/10.1182\/blood-2011-06-275610.","journal-title":"Blood"},{"issue":"7","key":"701_CR63","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrc2439","volume":"8","author":"RG Ramsay","year":"2008","unstructured":"Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer. 2008;8(7):523\u201334. https:\/\/doi.org\/10.1038\/nrc2439.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"701_CR64","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1080\/15384101.2018.1480218","volume":"17","author":"KM Kodigepalli","year":"2018","unstructured":"Kodigepalli KM, Bonifati S, Tirumuru N, Wu L. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle. 2018;17(9):1124\u201337. https:\/\/doi.org\/10.1080\/15384101.2018.1480218.","journal-title":"Cell Cycle"},{"issue":"48","key":"701_CR65","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.1038\/sj.onc.1208850","volume":"24","author":"M Bousquet","year":"2005","unstructured":"Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene. 2005;24(48):7248\u201352. https:\/\/doi.org\/10.1038\/sj.onc.1208850.","journal-title":"Oncogene"},{"key":"701_CR66","doi-asserted-by":"publisher","unstructured":"Peng L, Shi R, Dai Q, Yang H, Ye L, Wang Y, et al. Prognostic relevance of structural maintenance of chromosomes 4 overexpression in pediatric acute lymphoblastic leukemia. Clin Lab. 2022;68(1):210852. https:\/\/doi.org\/10.7754\/Clin.Lab.2021.210852.","DOI":"10.7754\/Clin.Lab.2021.210852"},{"issue":"10","key":"701_CR67","doi-asserted-by":"publisher","first-page":"13617","DOI":"10.1007\/s13277-016-5182-z","volume":"37","author":"M Jasek","year":"2016","unstructured":"Jasek M, Bojarska-Junak A, Wagner M, Sobczy\u0144ski M, Wo\u0142owiec D, Roli\u0144ski J, et al. Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia. Tumour Biol. 2016;37(10):13617\u201326. https:\/\/doi.org\/10.1007\/s13277-016-5182-z.","journal-title":"Tumour Biol"},{"issue":"5","key":"701_CR68","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s12185-012-1051-8","volume":"95","author":"E Orouji","year":"2012","unstructured":"Orouji E, Tavakkol Afshari J, Badiee Z, Shirdel A, Alipour A. Association between HLA-DQB1 gene and patients with acute lymphoblastic leukemia (ALL). Int J Hematol. 2012;95(5):551\u201355. https:\/\/doi.org\/10.1007\/s12185-012-1051-8.","journal-title":"Int J Hematol"},{"issue":"7","key":"701_CR69","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/jcb.25845","volume":"118","author":"JC Fernandes","year":"2017","unstructured":"Fernandes JC, Rodrigues Alves APN, Machado-Neto JA, Scopim-Ribeiro R, Fenerich BA, et al. IRS1\/\u03b2-catenin axis is activated and induces MYC expression in acute lymphoblastic leukemia cells. J. Cell. Biochem. 2017;118(7):1774\u201381. https:\/\/doi.org\/10.1002\/jcb.25845.","journal-title":"J. Cell. Biochem"},{"key":"701_CR70","doi-asserted-by":"publisher","unstructured":"Matthijssens F, Sharma ND, Nysus M, Nickl CK, Kang H, Perez DR, et al. RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. J. Clin. Invest. 2021;131(6):141566. https:\/\/doi.org\/10.1172\/JCI141566.","DOI":"10.1172\/JCI141566"},{"issue":"11","key":"701_CR71","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1038\/leu.2009.144","volume":"23","author":"A Farfsing","year":"2009","unstructured":"Farfsing A, Engel F, Seiffert M, Hartmann E, Ott G, Rosenwald A, et al. Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia. Leukemia. 2009;23(11):2018\u201326. https:\/\/doi.org\/10.1038\/leu.2009.144.","journal-title":"Leukemia"},{"key":"701_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2023.04.030","volume":"661","author":"C Li","year":"2023","unstructured":"Li C, Wang Z, Wei B, Liu Z, Li B, Kang H, et al. Upregulation of ROBO3 promotes proliferation, migration and adhesion of AML cells and affects the survival of AML patients. Biochem Biophys Res Commun. 2023;661:1\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2023.04.030.","journal-title":"Biochem Biophys Res Commun"},{"key":"701_CR73","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cca.2021.06.013","volume":"520","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Zhang L, Tu M, Yin X, Cai L, Zhang S, et al. Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma. Clin. Chim. Acta. 2021;520:126\u201332. https:\/\/doi.org\/10.1016\/j.cca.2021.06.013.","journal-title":"Chim. Acta"},{"key":"701_CR74","doi-asserted-by":"publisher","first-page":"845036","DOI":"10.3389\/fonc.2022.845036","volume":"12","author":"Q Jin","year":"2022","unstructured":"Jin Q, Zhao J, Zhao Z, Zhang S, Sun Z, Shi Y, et al. CAMK1D inhibits glioma through the PI3K\/AKT\/mTOR signaling pathway. Front Oncol. 2022;12:845036. https:\/\/doi.org\/10.3389\/fonc.2022.845036.","journal-title":"Front Oncol"},{"key":"701_CR75","doi-asserted-by":"publisher","first-page":"676124","DOI":"10.3389\/fonc.2021.676124","volume":"11","author":"X Lu","year":"2021","unstructured":"Lu X, Li C, Xu W, Wu Y, Wang J, Chen S, et al. Malignant tumor purity reveals the driven and prognostic role of CD3E in low-grade glioma microenvironment. Front Oncol. 2021;11:676124. https:\/\/doi.org\/10.3389\/fonc.2021.676124.","journal-title":"Front Oncol"},{"issue":"3","key":"701_CR76","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4149\/neo_2020_190711N624","volume":"67","author":"L Zhang","year":"2020","unstructured":"Zhang L, Yang P, Liu Q, Wang J, Yan F, Duan L, et al. KLF8 promotes cancer stem cell-like phenotypes in osteosarcoma through miR-429-SOX2 signaling. Neoplasma. 2020;67(3):519\u201327. https:\/\/doi.org\/10.4149\/neo_2020_190711N624.","journal-title":"Neoplasma"},{"issue":"9","key":"701_CR77","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1158\/0008-5472.CAN-17-3644","volume":"78","author":"L He","year":"2018","unstructured":"He L, Tang J, Andersson EI, Timonen S, Koschmieder S, Wennerberg K, et al. Patient-customized drug combination prediction and testing for T-cell prolymphocytic leukemia patients. Cancer Res. 2018;78(9):2407\u201318. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3644.","journal-title":"Cancer Res"},{"issue":"S2","key":"701_CR78","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/hon.161_2631","volume":"37","author":"CF Kornauth","year":"2019","unstructured":"Kornauth CF, Herbaux C, Boidol B, Guillemette C, Mayerh\u00f6fer ME, J\u00e4ger U, et al. The combination of venetoclax and ibrutinib is effective in relapsed\/refactory T-prolymphocytic leukemia and influences BCL-2-family member dependencies. Hematol Oncol. 2019;37(S2):482\u201384. https:\/\/doi.org\/10.1002\/hon.161_2631.","journal-title":"Hematol Oncol"},{"issue":"8","key":"701_CR79","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.3324\/haematol.2020.271304","volume":"106","author":"CF Kornauth","year":"2021","unstructured":"Kornauth CF, Herbaux C, Boidol B, Guillemette C, Caron P, Mayerh\u00f6fer ME, et al. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica. 2021;106(8):2251\u201356. https:\/\/doi.org\/10.3324\/haematol.2020.271304.","journal-title":"Haematologica"},{"issue":"8","key":"701_CR80","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1517\/13543780903071038","volume":"18","author":"S Spurgeon","year":"2009","unstructured":"Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: Not just another purine analogue? Expert Opin Investig Drugs. 2009;18(8):1169\u201381. https:\/\/doi.org\/10.1517\/13543780903071038.","journal-title":"Expert Opin Investig Drugs"},{"key":"701_CR81","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2017.07.019","volume":"405","author":"SA Moharram","year":"2017","unstructured":"Moharram SA, Shah K, Khanum F, Marh\u00e4ll A, Gazi M, Kazi JU. Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia. Cancer Lett. 2017;405:73\u201378. https:\/\/doi.org\/10.1016\/j.canlet.2017.07.019.","journal-title":"Cancer Lett"},{"issue":"12","key":"701_CR82","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1038\/s41375-023-02057-x","volume":"37","author":"KB Johansson","year":"2023","unstructured":"Johansson KB, Zimmerman MS, Dmytrenko IV, Gao F, Link DC. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia. 2023;37(12):2356\u201366. https:\/\/doi.org\/10.1038\/s41375-023-02057-x.","journal-title":"Leukemia"},{"key":"701_CR83","doi-asserted-by":"publisher","unstructured":"Pal I, Illendula A, Joyner A, Manavalan JS, Deddens TM, Sabzevari A, et al. Preclinical development of a romidepsin nanoparticle demonstrates Superior tolerability and efficacy in models of human T-Cell lymphoma and large granular lymphocyte leukemia. bioRxiv [Preprint] 2024;23:2024\u20130718603379. https:\/\/doi.org\/10.1101\/2024.07.18.603379.","DOI":"10.1101\/2024.07.18.603379"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-025-00701-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-025-00701-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-025-00701-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:12:24Z","timestamp":1781611944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-025-00701-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1186\/s13062-025-00701-3","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Blood samples of patients were obtained under institutional review board-approved protocols after written informed consent according to the Declaration of Helsinki. The considered T-PLL sample collections and use have been approved for research purposes by the ethics committees of the University Hospital of Cologne (number 19\u20131089) and the University of Helsinki (303\/13\/03\/01\/2011).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}